Hoan My Medical Group and Gene Solutions Sign Strategic Partnership: Expanding Access to International-Standard Genetic Testing

Ho Chi Minh City, October 15, 2025 – Hoan My Medical Group and Gene Solutions held a strategic partnership signing ceremony, attended by Ms. Huynh Bich Lien, Chief Executive Officer of Hoan My Medical Group, and Dr. Nguyen Huu Nguyen, Co-founder and Deputy CEO of Gene Solutions, along with senior representatives from both organizations. 

This collaboration aims to expand access for patients in Vietnam to world-class genetic testing, including non-invasive prenatal screening, early cancer detection solutions, and precision oncology support. 

Comprehensive Partnership Delivering Tangible Benefits for Patients 

Under the strategic Memorandum of Understanding, Hoan My Medical Group and Gene Solutions will jointly implement integrated processes for consultation, testing, and multidisciplinary review in the following areas for patients visiting Hoan My hospitals and clinics: 

• Non-invasive prenatal testing (NIPT) and advanced prenatal genetic diagnostics 

• Cancer screening and treatment support: ctDNA analysis for early cancer detection and personalized therapy guidance 

• Screening and diagnosis of rare genetic disorders and metabolic conditions in newborns 

• Genetic diagnostics for infertility and recurrent pregnancy loss 
• Plus a range of other precision medicine solutions tailored to different stages of care 

The partnership also includes joint scientific research, continuous medical education programs, and customer care initiatives such as the triSure-VIP Card, along with community outreach campaigns to raise awareness about genetic health. 

Leadership Perspectives 

Ms. Huynh Bich Lien, Group CEO of Hoan My Medical Corporation, shared:
“Through this collaboration, we aim to provide our patients and customers with early access to advanced genetic solutions and cutting-edge testing right at Hoan My facilities. These innovations will support accurate diagnosis and personalized treatment, optimizing care plans for each individual. Furthermore, training programs and scientific seminars under this partnership will enhance our clinicians’ expertise in genetics, ultimately improving service quality and patient care.” 

Dr. Nguyen Huu Nguyen, Co-founder and Deputy CEO of Gene Solutions, added:
“Genetic insights and precision medicine are shaping the future of healthcare—bridging the gap between laboratory science and clinical practice. Each test result from Gene Solutions gives doctors a clearer understanding of a patient’s molecular biology, disease mechanisms, and genetic factors. These insights enable clinicians to detect disease earlier, personalize treatment plans, choose the right therapies, and monitor progress at critical moments. As healthcare needs continue to grow, we believe this partnership will bring scientific innovation into everyday care, making world-class genetic testing more accessible and affordable for patients.”  

About Hoan My Medical Corporation

Hoan My Medical Corporation is Vietnam’s largest private healthcare network with 15 hospitals and three clinics, providing comprehensive services across its Hanh Phuc, Hoan My, and Thuan My brands. With over 5,000 dedicated medical professionals, Hoan My serves more than five million patient visits annually. Hoan My Medical Corporation is committed to delivering care with heart to patients across Vietnam, shaping the culture of the medical industry by increasing access to healthcare, setting new standards of clinical excellence, and pioneering innovative treatments and services.

About Gene Solutions 

Gene Solutions is a multinational biotechnology company at the forefront of genetic testing and research innovation across the Asia-Pacific region. Leveraging Next-Generation Sequencing (NGS) and Artificial Intelligence, the company offers a comprehensive portfolio of advanced solutions, including: 

• Next-generation non-invasive prenatal testing (NIPT) that covers both fetal abnormalities and maternal health indicators. 

• Clinically validated multi-cancer screening using multi-omics circulating tumor DNA (ctDNA) technology for early detection and tumor-of-origin localization. 

• Comprehensive genomic and transcriptomic profiling combined with clinically validated ctDNA-based molecular residual disease (MRD) monitoring to guide precision treatment and track disease progression. 

With over two million genetic tests delivered, Gene Solutions is recognized for its proprietary research, CAP-accredited laboratories, and contributions to advancing precision medicine through clinical studies, technology development, and regional collaborations.